Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154244 | 0.87 | CFTR (0.56) | F12NR1H2BAZ2BLMNAMAPT | |
| SCHEMBL1841280 | 0.87 | LMNA (0.46) | F12NR1H2BAZ2BLMNAMAPT | |
| SCHEMBL2244149 | 0.85 | CTSK (0.52) | F12NR1H2BAZ2BLMNAMAPT | |
| SCHEMBL1845995 | 0.85 | CTSK (0.51) | F12NR1H2BAZ2BLMNAMAPT | |
| SCHEMBL1843650 | 0.85 | CTSK (0.51) | F12BAZ2BLMNAMAPTCFTR | |
| SCHEMBL5512666 | 0.84 | MAPT (0.53) | F12BAZ2BLMNAMAPTCFTR | |
| SCHEMBL2241936 | 0.81 | MAPT (0.69) | BAZ2BLMNAMAPTCFTRPABPC1 | |
| SCHEMBL29357331 | 0.81 | MAPT (0.69) | BAZ2BLMNAMAPTCFTRPABPC1 | |
| SCHEMBL4791778 | 0.80 | CGAS (0.45) | F12NR1H2BAZ2BLMNAMAPT | |
| SCHEMBL5511793 | 0.80 | LMNA (0.51) | F12BAZ2BLMNAMAPTCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7183282-B2 | Substituted heterocycle fused γ-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2006-07-06 | — | — | US | disclosed |
| US-7071186-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1189904-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | ROBICHAUD ALBERT J (US) | 2004-02-19 | — | — | US | disclosed |
| US-6552017-B1 | As serotonin agonists and antagonists and are useful in the control or prophylaxis of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | F12 1051/4885NR1H2 294/4885BAZ2B 1689/4885 |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | HTR2B, HTR1B, HTR3B | F12 690/4885NR1H2 302/4885BAZ2B 1007/4885 |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | F12 1051/4885NR1H2 294/4885BAZ2B 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.